AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06754241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Care
Description: (1) Intervention Day 1: (i) All patients in the observation group were provided with an introduction to the study and invited to join the WeChat group for the observation group. (2) Intervention Day 2: Exercise guidance for patients with KOA was shared via the WeChat group.(3) Intervention Day 3: Guidance for emotional regulation was sent to the patients with KOA via the WeChat group.(4) Intervention Week 1: A micro-lesson on KOA-related knowledge was delivered via the WeChat group to deepen patients' understanding. (5) Intervention Week 2: (i) Text instructions and related questions on common conservative treatments for KOA, including topical and oral painkillers, were shared, with correct answers provided the next day.(ii) A micro-lesson on exercise guidance for patients with KOA was uploaded to the WeChat group to reinforce patients' understanding.
Study NCT06755567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-based radiomics-clinical model
Description: Response to NACI was predicted using MRI-based radiomics-clinical model.
Study NCT06753396 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Platelet rich fibrin
Description: The injectable platelet rich fibrin will be integrated into the tissue by subgingival and submucosal application to the keratinized gingiva of the implant sites with insufficient peri-implant soft tissue phenotype. Then, the prepared injectable platelet rich fibrin will be injected into the mucogingival junction apical to the keratinized gingival site. This procedure will be repeated 3 times in total, 1 time in 30 days for 3 months.
Study NCT06753786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Study NCT06753786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Study NCT06756139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy mobile application
Description: The CBT mobile application enables patients to conduct cognitive therapy independently.
Study NCT06756139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flupentixol and Melitracen Tablets
Description: patients take Flupentixol and Melitracen Tablets
Study NCT06753019 — intervention group
Intervention type: OTHER
Intervention: survey assessment tools
Description: Functional and psychological status and the level of somatosensory amplification in patients with knee osteoarthritis will be evaluated with questionnaires.
Study NCT06755242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-077
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06756009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmic examination
Description: Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
Study NCT06756009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: General Condition Examination
Description: Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
Study NCT06754488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Reconstruction
Description: Reconstruct the bladder neck using the inverted tennis racket method to narrow the bladder neck opening and lengthen the posterior bladder wall. Measure the length of the extended part.
Study NCT06754488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior suspension
Description: The anterior wall of the bladder was continuously sutured and fixed onto the muscular membrane of the lower margin of the symphysis pubis using a 3-0 barb suture.
Study NCT06751862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 150g of fat with glucose
Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of glucose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
Study NCT06751862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 150g of fat with fructose
Description: Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of fructose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
Study NCT06751862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 150g of fat with sucrose
Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of sucrose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
Study NCT06751862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short-term (7 days) fructose restriction
Description: Subjects will receive a package of glucose and selected foods without fructose to supplement their diet. For seven days they then will adhere to the diet without fructose and keep the detailed dietary record.
Study NCT06750666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: De-implementation of Urinary Dipsticks
Description: In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
Study NCT06750666 — intervention group
Intervention type: OTHER
Intervention: Usual practice with no intervention
Description: In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
Study NCT06754566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Assisted Rehabilitation with Strategy Training
Description: CAR-ST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing daily activity limitations after stroke. The caregiver, as an active partner, not only supervises the participant but also co-participates in the practice. Caregivers are instructed on when and how to provide assistance during task practice, using physical, verbal, or visual guidance. As the participant's performance improves, the caregiver is empowered to motivate them to exert greater efforts, encouraging higher repetitions, longer durations of the same task, and an increased level of difficulty.
Study NCT06754566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Training
Description: Compared to CAR-ST, ST is a home-based rehabilitation that guides stroke survivors only to implement strategy training for addressing daily activity limitations after stroke.
Study NCT06754566 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
Study NCT06753292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active gas aspiration
Description: surgeon will be instructed to actively aspirate the intraperitoneal CO2 gas
Study NCT06753292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary recruitment maneuver
Description: patients will receive the PRM which consisted of five manual pulmonary inflations, where each positive pressure inflation will be done for 5 s at a maximum pressure of 30 cm H2O, manually by using the APL valve in the anesthesia machine. The patient will be in a Trendelenburg position (30°). The fifth positive pressure inflation lasted for approximately 5 s. During that time, the patient will be closely monitored, while the anesthesiologist performed PRM
Study NCT06752525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).
Study NCT06752525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate 500 mg
Description: patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).
Study NCT06752798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib + Cisplatin
Description: Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
Study NCT06753305 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gingivectomy and gingivoplasty surgery and periodontal paste +ozone therapy application
Description: After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Periodontal paste (Coe-pak) will be applied to the area left for secondary healing after ozone therapy (activated oxygen (Cure 09 Active Oxygen))
Study NCT06753305 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gingivectomy and gingivoplasty surgery and periodontal paste application
Description: After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Only periodontal paste will be applied after the surgery.
Study NCT06752369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1D-specific depression SSI
Description: The T1D-specific depression SSI will include 1) psychoeducation about depression, including how behavior shapes feelings and thoughts, 2) a values assessment, where youth will identify key areas (i.e., family relationships, friendships, school, or hobbies) from which they draw (or once drew) enjoyment and meaning, and 3) the creation of an activity action plan, wherein youth identify (from pre-generated lists) and personalize (in guided exercises) three activities to target for change.
Study NCT06752369 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: T1D Educational
Description: T1D Educational Material
Study NCT06753994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor
Description: Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
Study NCT06753669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education and social network building
Description: The investigators will use techniques from the social network literature to build each treatment group as a cohesive social network and will diffuse educational messages through these groups.
Study NCT06753669 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dental referral and educational materials
Description: Control arm will receive a referral to vetted dentist and educational materials on child health
Study NCT06755060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted medical decision support system
Description: The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. Patients in the intervention group will undergo standard ophthalmic examinations, with clinical decisions guided by the recommendations generated by the AI system. In contrast, patients in the control group will receive only standard ophthalmic examinations and treatment, without the support of AI-assisted decision-making tools.
Study NCT06754163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)
Description: Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet.
Study NCT06753422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: 200 ml/day kefir~The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota.
Study NCT06751979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: Daily intake of a lozenge containing the probiotic strain S. salivarius M18.
Study NCT06751979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06751667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary biomarkers
Description: In a bid to reduce or replace surveillance cystoscopies multiple urinary biomarkers have been evaluated for the follow-up of the bladder cancer patients. These device will reduce the number of cystoscopies
Study NCT05073510 — intervention group
Intervention type: DEVICE
Intervention: BVE
Description: Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opevesostat
Description: Administered orally
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered orally
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Administered orally or IM as a rescue drug
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Administered orally
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone acetate
Description: Administered orally
Study NCT06136650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Administered orally
Study NCT05321498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week.
Study NCT05321498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be delivered by subcutaneous injection once a week
Study NCT06302101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: chair-based exercises
Description: Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises.
Study NCT06302101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chair-based exercises
Description: Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises.
Study NCT06302101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive exercises
Description: Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
Study NCT05958719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide 30mg biw, p.o, 21 days for a cycle.
Study NCT05160623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 1 % Topical Solution
Description: Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
Study NCT05958719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.
Study NCT05958719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal mitoxantrone
Description: 12mg/m2， d1,21 days for a cycle.
Study NCT05958719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m2，d1-5,21 days for a cycle.
Study NCT06269770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Description: Add tapentadol, for effective pain management in a multimodal setting during TKR.
Study NCT06269770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Add tramadol, for effective pain management in a multimodal setting during TKR.
Study NCT04712942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
Study NCT04712942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
Study NCT04712942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
Study NCT05349617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvant
Description: PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
Study NCT05349617 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is comprised of formulation buffer
Study NCT05881759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised ESBA
Description: Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
Study NCT04497168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: 20mg daily
Study NCT04497168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pills
Study NCT05981768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline